Naseer Nasser, MD
Interventional Cardiology · Michigan City, INNPI 1063436582
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (51.9%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Abbott at 48.8% of the total. Reporting peaked in 2019 at $4,306 and has fallen 95.8% since, to $179 in 2025.
Across 95 payments — averaging $108.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Boston Scientific$3K
- Medtronic$2K
- Abiomed$302
- Edwards Lifesciences$213
- Novartis$103
- plus $447 from 13 others
What the payments were for
- Speaking & faculty fees$2,00019%
- Travel & lodging$5,35752%
- Food & beverage$2,68526%
- Education$2763%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 28 | $5,034 |
| Boston Scientific | 16 | $2,560 |
| Medtronic(2 entities) | 15 | $1,659 |
| Abiomed | 7 | $302 |
| Edwards Lifesciences | 5 | $213 |
| Novartis | 7 | $103 |
| Biotronik Inc. | 1 | $100 |
| Inari Medical, Inc. | 1 | $72 |
| Shockwave Medical, Inc | 2 | $47 |
| Biosense Webster, Inc. | 1 | $32 |
| Pfizer | 2 | $32 |
| Heartflow, Inc. | 1 | $31 |
| Philips North America LLC | 1 | $25 |
| Penumbra, Inc. | 1 | $23 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $22 |
| Scpharmaceuticals Inc. | 1 | $21 |
| Cardiva Medical, Inc. | 1 | $19 |
| Kestra Medical Technology Services, Inc. | 1 | $18 |
| Cardiovascular Systems Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,318 in reported general payments places this provider in the 60th percentile of 170 interventional cardiology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 74 | $83,066 |
| XareltoRivaroxaban | 63 | $78,329 |
| EntrestoSacubitril/Valsartan | 24 | $35,237 |
| BrilintaTicagrelor | 26 | $18,209 |
| Flecainide Acetate | 44 | $3,679 |
| Amiodarone Hcl | 44 | $3,217 |
| Varenicline Tartrate | 24 | $2,924 |
| Dofetilide | 23 | $2,770 |
| ClopidogrelClopidogrel Bisulfate | 166 | $1,578 |
| Prasugrel Hcl | 19 | $1,556 |
| Metoprolol Succinate | 125 | $1,433 |
| Atorvastatin Calcium | 108 | $1,249 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 36 | $871 |
| Propafenone Hcl | 14 | $650 |
| Carvedilol | 54 | $549 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $32 | $83,06674 claims |
| NovartisEntresto | $103 | $35,23724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 170 interventional cardiology providers in Indiana.
Other interventional cardiology in Michigan City
- Sammi DaliMichigan City$17K
- Michael FlisakMichigan City$11K
- Samer AbbasEast Chicago$395K
- James HermillerIndianapolis$307K
- Woodrow CoreyIndianapolis$262K
- Muzammil MusaniFort Wayne$184K
- Dean FerreraEast Chicago$180K
- Shashidhar DivakaruniMunster$97K
- Jarrod FrizzellEvansville$86K
- Navneet LatherNoblesville$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.